GordonMD Global Investments LP — 13F Holdings & Portfolio
CIK 2039349 · latest 13F-HR filed 2026-08-14
GordonMD Global Investments LP manages $206.7M in 13F-reported U.S. long-equity assets across 16 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are KYTX (18.30%), PYXS (14.60%), TSHA (11.86%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position and exited 1; 9 existing positions rose in reported value and 1 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 83.9%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 26, 2026.
SUITE 420
BEVERLY HILLS, CA 90212
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| GORDON, CRAIG, DAVID Control | LIMITED PARTNER, CEO, CIO since Jun 2021 | 75% or more | Individual |
| GORDONMD GLOBAL INVESTMENTS GP LLC Control | GENERAL PARTNER since Jun 2021 | Less than 5% | Domestic Entity |
| KOSTOLANSKY, MICHAEL, JOSEPH | COO, CCO, CFO since Mar 2024 | Less than 5% | Individual |
| GORDON, CRAIG, DAVID Control Indirect owner via GORDONMD GLOBAL INVESTMENTS GP LLC | MANAGING MEMBER AND MEMBER since Jun 2021 | 75% or more | Individual |
Ownership & leadership changes · 6 filings with changes since Sep 20, 2021
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedKOSTOLANSKY, MICHAEL, JOSEPH · title COO & CCO → COO, CCO, CFO
- ChangedKOSTOLANSKY, MICHAEL, JOSEPH · title CCO & COO → COO & CCO
- AddedKOSTOLANSKY, MICHAEL, JOSEPH · CCO & COO · Less than 5%
- ChangedGORDON, CRAIG, DAVID · title LIMITED PARTNER, CEO, CIO, CCO → LIMITED PARTNER, CEO, CIO
- No longer listedBONGIOVANNI-BLASUCCI, ROXANNE, VICTORIA · CHIEF COMPLIANCE OFFICER AND COO · Less than 5% · control person · listed since Jan 2023
- ChangedGORDON, CRAIG, DAVID · title LIMITED PARTNER, CEO, CIO → LIMITED PARTNER, CEO, CIO, CCO
- ChangedGORDON, CRAIG, DAVID · title CEO, CIO, OWNER → LIMITED PARTNER, CEO, CIO
- ChangedGORDON, CRAIG, DAVID · indirect via GORDONMD GLOBAL INVESTMENTS GP LLC: title OWNER → MANAGING MEMBER AND MEMBER
- AddedBONGIOVANNI-BLASUCCI, ROXANNE, VICTORIA · CHIEF COMPLIANCE OFFICER AND COO · Less than 5% · control person
- ChangedGORDON, CRAIG, DAVID · title CHIEF COMPLIANCE OFFICER/OWNER → CEO, CIO, OWNER
- ListedGORDON, CRAIG, DAVID · CHIEF COMPLIANCE OFFICER/OWNER · 75% or more · control person
- ListedGORDON, CRAIG, DAVID · OWNER · 75% or more · indirect via GORDONMD GLOBAL INVESTMENTS GP LLC · control person
- ListedGORDONMD GLOBAL INVESTMENTS GP LLC · GENERAL PARTNER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- PYXIS ONCOLOGY INC$24.2M +401.4%
- TEVA PHARMACEUTICAL INDS LTD$10.7M +191.1%
- ALLOGENE THERAPEUTICS INC$7.5M +215.8%
- CELLDEX THERAPEUTICS INC NEW$5.0M +92.7%
- ULTRAGENYX PHARMACEUTICAL IN$3.6M +59.4%
GordonMD Global Investments LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | KYVERNA THERAPEUTICS INC | KYTX | 501976104 | $37.8M | 18.30% | 4,244,818 | SH |
| 2 | PYXIS ONCOLOGY INC | PYXS | 747324101 | $30.2M | 14.60% | 10,024,909 | SH |
| 3 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $24.5M | 11.86% | 723,185 | SH |
| 4 | TEVA PHARMACEUTICAL INDS LTD | TEVA | 881624209 | $16.4M | 7.92% | 2,402,495 | SH |
| 5 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $13.8M | 6.67% | 1,353,552 | SH |
| 6 | ALLOGENE THERAPEUTICS INC | ALLO | 019770106 | $11.0M | 5.33% | 5,298,000 | SH |
| 7 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $10.4M | 5.04% | 279,720 | SH |
| 8 | EDITAS MEDICINE INC | EDIT | 28106W103 | $10.1M | 4.90% | 3,127,000 | SH |
| 9 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $9.7M | 4.67% | 289,101 | SH |
| 10 | BAUSCH PLUS LOMB CORP | BLCO | 071705107 | $9.5M | 4.60% | 573,472 | SH |
| 11 | AMGEN INC | AMGN | 031162100 | $7.3M | 3.54% | 20,212 | SH |
| 12 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $7.3M | 3.53% | 132,500 | SH |
| 13 | SIONNA THERAPEUTICS INC | SION | 829401108 | $6.0M | 2.89% | 136,000 | SH |
| 14 | INCYTE CORP | INCY | 45337C102 | $4.9M | 2.38% | 43,300 | SH |
| 15 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $4.8M | 2.30% | 126,985 | SH |
| 16 | INSMED INC | INSM | 457669307 | $3.0M | 1.47% | 28,587 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $206.7M | 16 | 0000919574-26-005398 |
| 2026-03-31 | 2026-05-15 | $143.6M | 16 | 0000919574-26-003273 |
| 2025-12-31 | 2026-02-17 | $139.5M | 13 | 0000919574-26-001152 |
SUITE 420
BEVERELY HILLS, CA 90212